LumiraDx Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and LumiraDx are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days LumiraDx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, LumiraDx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 132.1 M | |
| Total Cashflows From Investing Activities | -25 M |
LumiraDx |
LumiraDx Relative Risk vs. Return Landscape
If you would invest (100.00) in LumiraDx on December 27, 2024 and sell it today you would earn a total of 100.00 from holding LumiraDx or generate -100.0% return on investment over 90 days. LumiraDx is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than LumiraDx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
LumiraDx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LumiraDx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LumiraDx, and traders can use it to determine the average amount a LumiraDx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LMDX |
Based on monthly moving average LumiraDx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LumiraDx by adding LumiraDx to a well-diversified portfolio.
LumiraDx Fundamentals Growth
LumiraDx Stock prices reflect investors' perceptions of the future prospects and financial health of LumiraDx, and LumiraDx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LumiraDx Stock performance.
| Return On Equity | -15.64 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (2.67) % | |||
| Operating Margin | (2.31) % | |||
| Current Valuation | 440.16 M | |||
| Shares Outstanding | 161.02 M | |||
| Price To Earning | 13.70 X | |||
| Price To Book | 18.28 X | |||
| Price To Sales | 1.97 X | |||
| Revenue | 254.48 M | |||
| EBITDA | (273.54 M) | |||
| Cash And Equivalents | 106.45 M | |||
| Cash Per Share | 0.42 X | |||
| Total Debt | 401.25 M | |||
| Book Value Per Share | (0.67) X | |||
| Cash Flow From Operations | (162.11 M) | |||
| Earnings Per Share | (1.08) X | |||
| Total Asset | 441.01 M | |||
| Retained Earnings | (1.09 B) | |||
Things to note about LumiraDx performance evaluation
Checking the ongoing alerts about LumiraDx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LumiraDx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| LumiraDx is not yet fully synchronised with the market data | |
| LumiraDx has some characteristics of a very speculative penny stock | |
| LumiraDx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 254.48 M. Net Loss for the year was (449.19 M) with profit before overhead, payroll, taxes, and interest of 61.02 M. | |
| LumiraDx currently holds about 106.45 M in cash with (162.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.42. | |
| Roughly 55.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing LumiraDx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LumiraDx's stock is overvalued or undervalued compared to its peers.
- Examining LumiraDx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LumiraDx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LumiraDx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LumiraDx's stock. These opinions can provide insight into LumiraDx's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |